

Pitt Street Research issues Initiation Report on Azure Health Technology Limited trading as VGI Health Technology (NSX:VTL)

Sydney New South Wales, 8 June 2021 – Azure Health Technology Limited trading as VGI Health Technology (the **Company** or **NSX:VTL**) is pleased to announce that Pitt Street Research has issued an Initiation Report which can be accessed at this link: <https://www.pittstreetresearch.com/vgi-health-technology>.

VTL's CEO and Managing Director, Dr Glenn Tong, said that the founder and senior analyst of Pitt Street Research, Stuart Roberts, was one of the most experienced research analysts in the Australian biotechnology industry.

"We are very pleased that Stuart Roberts has invested time into analysing the VTL story," Dr Tong said.

"Stuart has done a great job in articulating the value proposition which VTL presents and how similar companies have successfully commercialised pharmaceutical products derived from natural sources. He also explains in very clear and simple terms how VTL's drug development and nutraceuticals business will add considerable value to the Company."

For more information please contact:

Glenn Tong, CEO and Managing Director
Ph: +61 (0) 412 193 350

Catriona Glover, Company Secretary
Tel: +61 (0) 402 328 200

Andrew Crook, Investor and Media Relations
Ph: +61 (0) 419 788 431

About Azure Health Technology Limited trading as VGI Health Technology (NSX:VTL)

Azure Health Technology Limited trading as VGI Health Technology is an Australian public biotechnology company listed on the National Stock Exchange (NSX) with the ticker code NSX:VTL. VTL is developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines. For more information see: <https://www.azureht.com.au>. To track VTL on the NSX, see: <https://www.nsx.com.au/summary/VTL>. Investors interested in trading shares on the NSX should contact a broker who is an NSX Participant: https://www.nsx.com.au/broker_list_print.asp